Octapharma

Octapharma, a pharmaceutical preparation manufacturer based in CH, is committed to reducing its environmental impact. The company has set a long-term goal to achieve Net Zero emissions by 2050.

For the 2024 reporting year, Octapharma reported total Scope 1 and 2 emissions of approximately 53.9 million kg CO2e (market-based). Scope 3 emissions for the same period were substantial, with purchased goods and services accounting for approximately 102.3 million kg CO2e, and capital goods contributing about 93.5 million kg CO2e. Employee commute emissions were around 23.3 million kg CO2e, and business travel around 18.7 million kg CO2e.

In 2023, Octapharma's market-based Scope 1 and 2 emissions totalled approximately 57.9 million kg CO2e. Scope 3 emissions for 2023 included about 93.1 million kg CO2e from purchased goods and services, and approximately 72.0 million kg CO2e from capital goods. Employee commute was reported at 25.6 million kg CO2e, and business travel at 20.3 million kg CO2e.

Octapharma has a near-term target to reduce its overall emissions by 30% by 2028, compared to a 2019 baseline. The company has already achieved a 22% reduction in overall emissions since 2019.